Handelsblatt has identified iOmx as one of Germany’s most promising biotech startups

Handelsblatt, which focuses on business and finance, spoke with biotech experts from several venture capital firms. When asked about the most promising companies from the German biotech scene, iOmx was among the companies mentioned particularly frequently. The venture capital investors see great potential in the new therapeutic approaches of iOmx and the other top-ranked companies. Their assessment reflects confidence in the companies’ ability to develop successful new drugs.

iOmx Therapeutics focuses on the development of first-in-class cancer immunotherapies that address novel immune evasion mechanisms hijacked by cancer cells and thus have the potential to target cancers resistant to current immunotherapies.

The successful spin-off iOmx is based on years of research work by Prof. Philipp Beckhove, Scientific Director of the LIT, and his former PhD candidate Dr. Nisit Kandelwal. Prof. Beckhoves Research Division “Interventional Immunology” at the LIT further investigates cellular and molecular mechanisms by which tumors can protect themselves from immune attack. The division focuses on three closely linked fields of research: immune resistance mechanisms in tumor cells, regulation of anti-tumor immunity in situ and breaking immune resistance

For more information about iOmx Therapeutics visit the official website: https://iomx.com/